July 24, 2013

Even though customers may only buy certain OTC categories a few times a year, for consumer healthcare brands, the opportunities to have a more meaningful relationship in the lives of their consumers has never been greater, Stefan Merlo, director of healthcare strategy, Novartis Consumer Health, told DSNtv in a special edition of DSN Executive Viewpoints.

October 15, 2014

Camber Consumer Care, which focuses on both consumer care and prescription-to-OTC switch products, recently introduced new executives to its staff.

October 15, 2014

The resurgence of iconic pain relief brands Tylenol and Excedrin continue to contribute to the slight growth across internal analgesic tablets. It’s a $3.2 billion book of business across U.S. multi-outlets, according to IRI, that is up slightly by 0.8% for the 52 weeks ended Aug. 10. 

October 15, 2014

Could the regulatory and scientific logjam that’s keeping copycat biotech medicines off the market and out of the hands of patients and health providers in the United States finally be breaking?

October 14, 2014

Following the completion of a joint venture between GlaxoSmithKline and Novartis' consumer health units, Brian McNamara, currently division head, Novartis OTC, will transition to GSK as Head of Americas and Europe for the consumer health businesses.

September 30, 2014

Par Pharmaceutical on Tuesday announced that it has started shipping amlodipine and valsartan tablets in all four dosage strengths.

September 8, 2014

Camber Consumer Care, which focuses on both consumer care and prescription-to-OTC switch products, introduced new executives to its staff. 

September 2, 2014

Sandoz last week announced the U.S. market introduction of decitabine for injection, a generic version of Eisai’s Dacogen.

August 20, 2014

The lion’s share of the analgesics business may be in internal analgesics — sales of which totaled $3.6 billion, up 1.1% for the 52 weeks ended June 15 across total U.S. multi-outlets, according to IRI — but it’s alternative pain relievers that may represent the growth opportunity.

August 20, 2014

Excedrin relaunched in the United States in 2013 and is doing well. The brand generated $130 million between its Excedrin tablets and Excedrin Migraine tablets for the 52 weeks ended June 15 across total U.S. multi-outlets, according to IRI.

July 28, 2014

The Food and Drug Administration has accepted a license application by Sandoz, Novartis' generics company, for a potential generic biologic drug, the company announced Monday.

July 15, 2014

Novartis has entered into an agreement with a division of Google to in-license its “smart lens” technology for all ocular medical uses. 

July 14, 2014

Sandoz on Monday announced the introduction of tobramycin inhalation solution, USP into the U.S. market. The drug is an authorized generic version of Tobi from Novartis.

July 7, 2014

Sandoz announced the launch of valsartan tablets, an authorized generic version of Diovan tablets which is used for the treatment of high blood pressure.

July 3, 2014

Novartis on Wednesday announced that it has begun shipment of its seasonal influenza vaccines to customers in the U.S. market for the 2014-2015 season.

June 27, 2014

Ohm Labs, a wholly owned subsidiary of Ranbaxy Labs, on Friday announced that it received approval from the Food and Drug Administration to manufacture and market valsartan tablets in 40 mg, 80 mg, 160 mg and 320 mg dosage strengths.

June 19, 2014

Actavis confirmed that the U.S. District Court for the District of Delaware found certain claims of U.S. Patent Nos. 6,335,031 and 6,316,023 valid and infringed by the company's rivastigmine transdermal system, a generic version of Exelon Patch from Novartis.

June 17, 2014

Novartis on Tuesday announced that it had submitted a biologic license application to the Food and Drug Administration for marketing approval for the use of Bexsero.

May 16, 2014

These are interesting times to be in the OTC business, Matt Mannelly, Prestige Brands president and CEO, told analysts Thursday.

May 15, 2014

Teva Pharmaceutical was denied in its suit to block approval of Mylan's and Sandoz' generic Copaxone, a multiple sclerosis, drug 10 days before the patent on the medication expires, according to a Bloomberg report published Thursday morning.

May 9, 2014

CorePharma on Thursday announced the launch of methylphenidate hydrochloride tablets USP, the generic version of Ritalin from Novartis.

April 22, 2014

Following a multifaceted deal with Novartis on Tuesday, GlaxoSmithKline and Novartis have created a consumer healthcare giant with annual worldwide revenues of $11 billion on a 2013 pro forma basis.

April 22, 2014

Novartis on Tuesday made a number of moves that have fundamentally reshaped its business, according to published reports.

April 7, 2014

Mallinckrodt and Questcor Pharmaceuticals on Monday announced that they have entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction valued at approximately $5.6 billion.